Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Hallador Energy Q1 2026 Earnings Call - $1.1B Capacity Deal Locks In 14-Year Revenue Visibility
Hallador Energy delivered a transformative milestone in its Q1 2026 earnings call, securing a 12-year, $1.1 billion capacity agreement that anchors forward revenue through 2040 at twice its historical...
- Hallador Energy secured a pivotal 12-year capacity agreement with a utility subsidiary, locking in over $1 billion in contracted revenue from 2028 through 2040 at pricing levels more than double its historical rates.
- The new agreement, combined with a March 2026 three-year capacity deal, places Hallador in a substantially sold-forward position on accredited capacity for approximately 14 consecutive years, providing unprecedented revenue visibility.
- Management explicitly differentiated between capacity and energy markets, noting that capacity is the current bottleneck for large load development while energy demand follows a multi-year lag as data centers and industrial projects come online.
- +7 more takeaways
Energy Recovery Inc. Q1 2026 Earnings Call - CEO Retirement, Middle East Guidance Withdrawn, New PX Q650 Launches
Energy Recovery reported a quarter defined by strategic transitions and geopolitical friction. CEO David Moon announced his retirement, while interim CFO Aidan Ryan stepped in after Mike Mancini’s dep...
- CEO David Moon announced his retirement, with a search for his successor underway. Interim CFO Aidan Ryan took over after Mike Mancini resigned.
- Launched the PX Q650 in March, securing its first commercial order and actively designing it into large desalination plants.
- Withdrew 2026 financial guidance for both desalination and wastewater due to uncertainty from the Middle East conflict.
- +9 more takeaways
Pattern Q1 2026 Earnings Call - Record NRR of 127% Drives Raised Full-Year Outlook
Pattern delivered a record start to 2026 with Q1 revenue surging 43% year-over-year to $774 million and adjusted EBITDA climbing 59% to $54 million. The company raised its full-year guidance, citing a...
- Q1 revenue grew 43% year-over-year to $774 million, driven by broad-based strength across existing brand partners, new marketplaces, and international expansion.
- Adjusted EBITDA reached $54 million, up 59% year-over-year, reflecting operating leverage despite increased R&D investments.
- Net revenue retention (NRR) hit a record 127%, up from 115% in the prior year, indicating strong expansion within the existing brand portfolio.
- +7 more takeaways
Warner Bros. Discovery Q1 2026 Earnings Call - Streaming Hits 140M Subscribers and Turns $2B Loss into Profit Ahead of Paramount Deal
Warner Bros. Discovery reported a strong Q1 2026, driven by streaming momentum and a successful content slate. HBO Max surpassed 140 million global subscribers, exceeding guidance, and the company tur...
- HBO Max surpassed 140 million global subscribers in Q1 2026, exceeding guidance, with management forecasting over 150 million by year-end.
- Streaming profitability has turned a corner, with the division generating $1.4 billion in profit last year after a $2 billion loss, signaling strong operating leverage.
- Warner Bros. Studios won 11 Oscars, including Best Picture for One Battle After Another, marking the studio’s most successful awards night in 103 years.
- +7 more takeaways
Vir Biotechnology Q1 2026 Earnings Call - Astellas Deal Closes as HDV Data Outpaces Competitors
Vir Biotechnology closed its $1.7B global partnership with Astellas for its T-cell engager VIR-5500, marking a transition from deal announcement to execution. The company received a $75M upfront equit...
- Vir Biotechnology closed its $1.7 billion global collaboration with Astellas for VIR-5500 on April 15, 2026, transitioning from deal announcement to active co-development and co-commercialization.
- The company received a $75 million upfront equity payment from Astellas and will receive an additional $240 million upfront payment within 30 days, significantly bolstering its balance sheet.
- Vir Biotechnology's cash runway is extended into the second half of 2028, supported by the Astellas deal proceeds and a $172.5 million follow-on equity offering closed in February 2026.
- +7 more takeaways
Sunrun Inc Q1 2026 Earnings Call - Direct Sales Ramp and Grid Infrastructure Play Accelerate Amid Industry Turmoil
Sunrun delivered a quarter of strategic acceleration, not just volume. The company added nearly 19,000 customers in Q1 2026, driving storage attachment rates to 73% and pushing contracted net value cr...
- Added nearly 19,000 customers in Q1 2026, with average system sizes up 5% and a 73% storage attachment rate, up 2 points from Q4.
- Contracted net value creation came in at $108 million, near the high end of the guided range of $25 million to $125 million, signaling strong unit economics.
- Aggregate contracted subscriber value reached $980 million, with unit value up 14% year over year, driven by larger systems and higher storage penetration.
- +7 more takeaways
Digi International Inc. FQ2 2026 Earnings Call - ARR Surges 50% as Record Margins and Cash Flow Fuel Growth
Digi International delivered a record-breaking fiscal second quarter, driven by a 50% year-over-year surge in annualized recurring revenue (ARR) to $184 million and a 25% jump in revenue to $131 milli...
- Fiscal Q2 2026 revenue reached $131 million, a 25% year-over-year increase and a quarterly record.
- Annualized recurring revenue (ARR) surged 50% year-over-year to $184 million, reflecting a successful shift toward subscription-based solutions.
- Gross margins hit an all-time high of 64%, up 190 basis points year-over-year, driven by favorable ARR mix and pricing discipline.
- +10 more takeaways
Arcutis Biotherapeutics Q1 2026 Earnings Call - ZORYVE Revenue Surges 65% Amid Record Cash Flow and Pediatric Expansion
Arcutis Biotherapeutics reported a sharp revenue jump in the first quarter of 2026, driven by relentless demand for ZORYVE and favorable shifts in payer contracting. Net product revenues climbed 65% y...
- Net product revenues reached $105.4 million, a 65% increase from Q1 2025, driven by rising patient demand and improved gross-to-net dynamics from formulary upgrades.
- ZORYVE captured 48% of new prescriptions within the branded nonsteroidal topical basket, outpacing competitors and signaling strong physician preference.
- Weekly prescription volumes stabilized around 21,000 per week after a seasonal and weather-impacted Q1, with Q2 showing a 13% month-over-month uptick.
- +7 more takeaways
Universal Technical Institute Q2 2026 Earnings Call - Demand Surges as AI Disrupts White-Collar Labor Markets
Universal Technical Institute reported a strong second quarter for fiscal 2026, with revenue rising nearly 7% to $221 million and new student starts jumping 14% year-over-year. Management reaffirmed i...
- Total new student starts increased 14% year-over-year, with the UTI division up 15% and Concorde up 13%, signaling durable demand across trades and healthcare.
- Revenue reached $221 million, up nearly 7% year-over-year, supported by scaling new campuses and program expansion.
- New campus execution is outpacing models, with the UTI San Antonio campus exceeding initial start projections by nearly 60%.
- +7 more takeaways
Alto Ingredients Q1 2026 Earnings Call - 45Z Credits and Export Premiums Drive Profitability
Alto Ingredients delivered a strong first quarter of 2026, turning a $12 million net loss in the prior year period into a $4 million net income. The turnaround was fueled by higher export sales, impro...
- Alto Ingredients reported Q1 2026 net income of $4 million ($0.05 per share), a stark reversal from the $12 million net loss in Q1 2025.
- Adjusted EBITDA surged to $4.7 million, up from negative $4.4 million in the prior year period, driven by higher export sales and improved crush margins.
- Consolidated net sales were $225 million, a 4% year-over-year decline in volume partially offset by a 4% increase in average sales price per gallon.
- +7 more takeaways